Edgestream Partners, L.P. Intellia Therapeutics, Inc. Transaction History
Edgestream Partners, L.P.
- $2.29 Billion
- Q4 2024
A detailed history of Edgestream Partners, L.P. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 12,974 shares of NTLA stock, worth $107,813. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,974Holding current value
$107,813% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding NTLA
# of Institutions
335Shares Held
94.9MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$104 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$84.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$79.8 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$43.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$31.7 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $632M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...